trending Market Intelligence /marketintelligence/en/news-insights/trending/a5eekruzx6rorvuwuobqaq2 content esgSubNav
In This List

MacroGenics starts common stock offering

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


MacroGenics starts common stock offering

MacroGenics Inc. initiated an underwritten public offering of 4.5 million common shares.

The company plans to grant the underwriters an option to buy up to an additional 675,000 shares.

Leerink Partners, Deutsche Bank Securities and Evercore ISI are acting as joint book-running managers of the proposed offering. Stifel and Nomura are acting as lead managers.

Rockville, Md.-based MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for treating cancer.